Le Lézard
Classified in: Health
Subject: FDA

Sucraid® (Sacrosidase) Oral Solution, The Only FDA-Approved Therapy To Treat Congenital Sucrase-Isomaltase Deficiency (CSID), Is Now Available


VERO BEACH, Fla., Oct. 2, 2018 /PRNewswire/ -- QOL Medical, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved its new, state-of-the-art manufacturing facility in Florida. The supply of Sucraid® (sacrosidase) Oral Solution has been restored. QOL Medical, LLC is now able to meet all prescription demand for Sucraid® nationwide without informed consent.

Sucraid® (sacrosidase) Oral Solution, for the Treatment of Congenital Sucrase-Isomaltase Deficiency

Congenital Sucrase-Isomaltase Deficiency (CSID) usually results in sucrose intolerance and gastrointestinal symptoms as a result of an individual's inability to properly digest sucrose (table sugar). Sucrose is found in a wide variety of foods including ice cream, apples, cake, corn, baked goods, and many processed foods common in Western diets. In adolescents and adults, CSID has been characterized by symptoms of chronic abdominal pain, gas, loose stools, and diarrhea. These symptoms are similar to, and can easily be confused with, those in mixed- and diarrhea-predominant irritable bowel syndrome (IBS), making an accurate differential diagnosis difficult. In infants, CSID classically presents as explosive watery diarrhea, failure to thrive, diaper rash, irritability, and acidic stools.

"FDA approval will provide broad access to a doctor-prescribed therapy for adults and children to help manage the symptoms of CSID," said Derick Cooper, CEO of QOL Medical, LLC, "since Sucraid® is the only FDA-approved enzyme replacement therapy for this condition."

Patients with a prescription may get a shipment of Sucraid® through the standard specialty pharmacy, US Bioservices, at 833-800-0122.

For more information, contact SucraidASSISTtm (Access and Support Services in Sucraid® Therapy) at 800-705-1962 or [email protected]. The SucraidASSISTtm program is designed to be the primary resource for Sucraid® patients, caregivers, and healthcare providers. One Patient Services manages the SucraidASSISTtm program to provide access to financial, peer, and dietary support for Sucraid® patients.

See Sucraid® Important Safety Information below.

About Sucraid®

Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID). Sucraid® can help improve the breakdown and absorption of sucrose (table sugar) from the intestine and can help relieve the gastrointestinal symptoms of CSID. www.sucraid.net

INDICATION
Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID). 

IMPORTANT SAFETY INFORMATION FOR SUCRAID® (SACROSIDASE) ORAL SOLUTION

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Click here for Sucraid® full prescribing information.

About CSID

Congenital sucrase-isomaltase deficiency (CSID), often referred to as Sucrose Intolerance, is an inherited disorder that causes fewer than normal amounts of certain digestive enzymes to be present. These enzymes are required to break down and absorb carbohydrates in your diet like table sugar (sucrose) and other sugars from starches present in foods such as potatoes and baked goods. If you have CSID and eat foods with sugars and starches, you may experience diarrhea, gas, bloating, and abdominal pain. 

About QOL Medical, LLC

QOL Medical is a specialty biopharmaceutical company dedicated to improving clinical outcomes and overall quality of life for patients with rare diseases. QOL Medical is a patient-centric company founded in 2003 to focus on the acquisition and commercialization of orphan and gastrointestinal products in underserved markets. Learn more at www.qolmed.com.

Sucraid® is a registered trademark of QOL Medical, LLC. All rights reserved.

Media Contact:
QOL Medical, LLC
Tiffany Carter
Phone: 818-720-8557
Email: [email protected]

Corporate Contact:
QOL Medical, LLC
3405 Ocean Drive
Vero Beach, FL 32963
Phone: 866-469-3773
Fax: 772-365-3375
Email: [email protected]

Specialty Pharmacy:
US Bioservices
Phone: 833-800-0122
https://www.usbioservices.com/contact-us

 

QOL Medical, LLC logo, 2017 (PRNewsfoto/QOL Medical LLC)

SOURCE QOL Medical, LLC


These press releases may also interest you

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: